23495-98-9CC[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12LJOQGZACKSYWCH-WZBLMQSHSA-N23495-98-9、522-66-7DTXSID70878516CHEMBL588934CHEBI:135994177.09 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards];175.29 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards];170.4 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards];174.69 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
Warning
H315 (97.6%): Causes skin irritation [Warning Skin corrosion/irritation];H319 (97.6%): Causes serious eye irritation [Warning Serious eye damage/eye irritation];H335 (95.1%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation]
P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 41 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.;Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.
M - Musculo-skeletal system;M09 - Other drugs for disorders of the musculo-skeletal system;M09A - Other drugs for disorders of the musculo-skeletal system;M09AA - Quinine and derivatives;M09AA01 - Hydroquinine
QM - Musculo-skeletal system;QM09 - Other drugs for disorders of the musculo-skeletal system;QM09A - Other drugs for disorders of the musculo-skeletal system;QM09AA - Quinine and derivatives;QM09AA01 - Hydroquinine
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS.
読み込み中…